Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term RECURRENCE. Found 9 abstracts

Corless CL, Ballman KV, Antonescu CR, Kolesnikova V, Maki RG, Pisters PW, Blackstein ME, Blanke CD, Demetri GD, Heinrich MC, von Mehren M, Patel S, McCarter MD, Owzar K, DeMatteo RP. Pathologic and Molecular Features Correlate With Long-Term Outcome After Adjuvant Therapy of Resected Primary GI Stromal Tumor: The ACOSOG Z9001 Trial. Journal of Clinical Oncology. 2014 May;32(15):1563-70.   PMCID: PMC 4026579
Kim SP, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer and Prostatic Diseases. 2014 Jun;17(2):163-9.   PMCID: No NIH funding
Zubek VB, Konski A. Cost Effectiveness of Risk-Prediction Tools in Selecting Patients for Immediate Post-Prostatectomy Treatment. Molecular Diagnosis & Therapy. 2009 Jan;13(1):31-47.
Wahl AO, Rademaker A, Kiel KD, Jones EL, Marks LB, Croog V, McCormick BM, Hirsch A, Karkar A, Motwani SB, Tereffe W, Yu TK, Sher D, Silverstein J, Kachnic LA, Kesslering C, Freedman GM, Small W. Multi-institutional review of repeat irradiation of chest wall and breast for recurrent breast cancer. International Journal of Radiation Oncology Biology Physics. 2008 Feb;70(2):477-84.
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
Henry LR, Sigurdson E, Ross EA, Lee JS, Watson JC, Cheng JD, Freedman GM, Konski A, Hoffman JP. Resection of isolated pelvic recurrences after colorectal surgery: Long-term results and predictors of improved clinical outcome. Annals of Surgical Oncology. 2007 Mar;14(3):1081-91.
Huse DM, von Mehren M, Lenhart G, Joensuu H, Blanke C, Feng WW, Finkelstein S, Demetri G. Cost effectiveness of imatinib mesylate in the treatment of advanced gastrointestinal stromal tumours. Clinical Drug Investigation. 2007 Jan;27(2):85-93.
Morrow M. Personalized surgical treatment of breast cancer. Breast Cancer Research. 2007 Jan;9:S12.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term RECURRENCE

RECURRENCE RADICAL PROSTATECTOMY MANAGEMENT Oncology radiotherapy THERAPY RISK FOLLOW-UP RADIATION-THERAPY SURVIVAL PCR RANDOMIZED-TRIAL LOCAL-REGIONAL RECURRENCE ANDROGEN DEPRIVATION DECISION-ANALYSIS but did not meet all of Prentice's significantly associated with CSS ADVANCED PROSTATE-CANCER SURVIVORS RECTAL-CANCER TUMOR EXTERNAL-BEAM RADIATION PREOPERATIVE NOMOGRAM NONCARRIERS hyperthermia SMALL-BOWEL SUCCINATE-DEHYDROGENASE the randomized treatment CONSERVATION THERAPY KIT GENE ECONOMIC-ANALYSIS SALVAGE MASTECTOMY RESPONSE RATES local recurrence CLINICAL UTILITY PROGNOSTIC MODELS BRAF MUTATIONS breast cancer colorectal cancer OVARIAN-CANCER RISK AB (Purpose:) under bar We evaluated whether posttreatment Gleason score and PSA stage-all of Prentice's requirements were not TYROSINE KINASE treatment recommendations WOMEN time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to IMATINIB MESYLATE SURGICAL SALVAGE indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier SARCOMAS GENE CONSERVING Inc Urology & Nephrology biochemical failure quality of life (Results: ) under bar After a median follow-up time of 59 years CARCINOMA PSA measurements) and cancer-specific survival (CSS) FAILURE prognostic models ANTIGEN MEN MORTALITY CLINICAL-TRIAL SDHA pelvis GIST recurrence HYPERTHERMIA 514 men with localized prostate cancer measurements in a cohort of 1 SURGERY ADENOCARCINOMA TRENDS FILLED TISSUE EXPANDERS ASSAY (T2c-4 and PSA level < 150 ng CURE DEATH we tested if PSADT was prognostic and Cox proportional hazards model outcomes (Conclusions) under bar Prostatic specific antigen doubling time is resection (P-Cox = 04) The significant posttreatment PSADTs were also LOW-RISK EPIDEMIOLOGY HISTORY independent of randomized treatment in this cohort The endpoints were survey PROGNOSTIC-FACTORS significant predictors of CSS (P-Cox < 0001) After adjusting for T AGONISTS (Methods and Materials: ) under bar We analyzed posttreatment PSA HORMONE or in combination with 24 65-70 Gy of radiation therapy (n = 761) PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < DEFINITION DIAGNOSIS and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted ANDROGEN SUPPRESSION men were randomized to neoadjuvant androgen deprivation and April 1995 prostatic-specific antigen doubling time (PSADT) was predictive of CANCER prostate cancer mortality by testing the Prentice requirements for a repeat irradiation CURATIVE SURGERY treated and monitored prospectively mL) RECEPTOR toxicity LOCAL the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint prostate cancer POSTOPERATIVE NOMOGRAM OUTCOMES
Last updated on Thursday, July 09, 2020